Covid - 19: Laboratoire Cerba Detects First Case of Omicron Variant in Mainland France
Retrieved on:
Thursday, December 2, 2021
Biotechnology, Managed Care, Other Health, Health, General Health, State, Local, Pharmaceutical, Medical Devices, Infectious Diseases, Hospitals, Public Policy, Government, CEO, Endocrinology, National Healthcare Group, Sertraline, Diagnosis, Health, General Directorate for Internal Security, Severe acute respiratory syndrome coronavirus 2, Vaccine, Epidemiology, Omicron, Charles de Gaulle Airport, Genetics, Lists of diseases, Risk, SARS, Public policy, Roissy, Public health, Medicine, Assistance Publique–Hôpitaux de Paris, Certification, Pharmaceutical industry, Medical imaging, laboratoire Cerba, Cerba HealthCare, LABORATOIRE CERBA, CERBA HEALTHCARE
Laboratoire Cerba, a global leader in specialized clinical pathology and member of the Cerba HealthCare Group, has detected a case of the Omicron variant from the sample of a patient arriving from Nigeria who was tested at Roissy Charles De Gaulle airport.
Key Points:
- Laboratoire Cerba, a global leader in specialized clinical pathology and member of the Cerba HealthCare Group, has detected a case of the Omicron variant from the sample of a patient arriving from Nigeria who was tested at Roissy Charles De Gaulle airport.
- The authorities - Sant Publique France [Public Health France], Agence Rgionale de Sant Ile de France [Paris Regional Health Agency] and Direction Gnrale de Sant [General Directorate for Health]- were immediately informed.
- Laboratoire Cerba, chosen last October by the French Health Authorities to participate in the Emergen consortium, carries out between 1,000 and 1,500 sequencings per week with results returned in less than 5 days.
- Cerba HealthCare, a leading player in medical diagnosis, aims to support the evolution of health systems towards more prevention.